Comparison · NCT01213173-4c2b4d71
Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm 1 - Active Comparator vs Arm 2 - Experimental: The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups. Trial comparisons, record NCT01213173-4c2b4d71. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01213173-4c2b4d71
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.216 | 0.15 | 0.299 | wilson | |
| Risk in group 2 | 0.243 | 0.174 | 0.329 | wilson | |
| Risk difference, group 1 minus group 2 | -0.028 | -0.136 | 0.0804 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.885 | 0.551 | 1.42 | log | |
| Odds ratio, group 1 over group 2 | 0.854 | 0.462 | 1.58 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm 1 - Active Comparator than on Arm 2 - Experimental | 35.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm 1 - Active Comparator | Drug: Succinate Metoprolol (Betaloc ZOK®) Treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks | 25 | 116 | OG000 |
| Group 2 | Arm 2 - Experimental | Drug: Succinate Metoprolol (Betaloc ZOK®) Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks | 28 | 115 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Proportion of Patients With Resting Heart Rate Controlled to ≤60bpm Between Groups
- Description
- Difference in proportions of patients who had resting heart rate controlled to ≤60 bpm after 2 weeks treatment between groups
- Time frame
- After 2 weeks treatment
- Population
ITT population was defined as all randomized subjects who had taken at least one dose of trial treatment, who had measurements at baseline for one or more efficacy variables and at least one post baseline measurement for the same variables in the treatment period.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients
- NCT number
- NCT01213173
- Phases
- PHASE4
- Conditions
- Angina Pectoris
- Interventions
- Succinate Metoprolol (Betaloc ZOK®), Succinate Metoprolol (Betaloc ZOK®)
- Lead sponsor
- AstraZeneca
- Results first posted
- 2013-08-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01213173?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01213173-4c2b4d71